Physician profile
Robert Ketchum
NPI 1578702197
$1,498.22
in general payments reported to CMS, 2019-2025
16 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.56 · 2024: $185 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.70 | 2021-2025 | |
| Qol Medical, LLC | $247.52 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $166.46 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $132.07 | 2025 | Entyvio |
| Novo Nordisk INC | $127.57 | 2025 | Wegovy |
| Gilead Sciences, INC. | $113.61 | 2024-2025 | |
| Genzyme Corporation | $61.96 | 2025 | |
| Janssen Biotech, INC. | $56.22 | 2024-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.40 | 2024 | Xifaxan |
| Ardelyx, INC. | $34.29 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $31.03 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $29.33 | 2025 | |
| Ferring Pharmaceuticals INC. | $28.54 | 2025 | Rebyota |
| Pfizer INC. | $22.87 | 2025 | |
| Aimmune Therapeutics, INC. | $21.72 | 2025 | Vowst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $17.93 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ketchum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.